107 related articles for article (PubMed ID: 29761323)
21. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
[TBL] [Abstract][Full Text] [Related]
22. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Andre F; Broglio K; Roche H; Martin M; Mackey JR; Penault-Llorca F; Hortobagyi GN; Pusztai L
J Clin Oncol; 2008 Jun; 26(16):2636-43. PubMed ID: 18509176
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
25. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent.
Yu KD; Fan L; Qiu LX; Ling H; Jiang YZ; Shao ZM
Oncotarget; 2017 Jul; 8(28):46549-46556. PubMed ID: 27447963
[TBL] [Abstract][Full Text] [Related]
26. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
27. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
28. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
[TBL] [Abstract][Full Text] [Related]
29. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Campone M; Lacroix-Triki M; Roca L; Spielmann M; Wildiers H; Cottu P; Kerbrat P; Levy C; Desmoulins I; Bachelot T; Winston T; Eymard JC; Uwer L; Duhoux FP; Verhoeven D; Jaubert D; Coeffic D; Orfeuvre H; Canon JL; Asselain B; Martin AL; Lemonnier J; Roché H
Eur J Cancer; 2018 Nov; 103():184-194. PubMed ID: 30267987
[TBL] [Abstract][Full Text] [Related]
30. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
[TBL] [Abstract][Full Text] [Related]
31. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
32. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Kerbrat P; Desmoulins I; Roca L; Levy C; Lortholary A; Marre A; Delva R; Rios M; Viens P; Brain É; Serin D; Edel M; Debled M; Campone M; Mourret-Reynier MA; Bachelot T; Foucher-Goudier MJ; Asselain B; Lemonnier J; Martin AL; Roché H
Eur J Cancer; 2017 Jul; 79():166-175. PubMed ID: 28501763
[TBL] [Abstract][Full Text] [Related]
33. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
34. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
35. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
37. Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.
Weerts MJA; Hollestelle A; Sieuwerts AM; Foekens JA; Sleijfer S; Martens JWM
Clin Cancer Res; 2017 Aug; 23(16):4735-4743. PubMed ID: 28420722
[No Abstract] [Full Text] [Related]
38. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
[TBL] [Abstract][Full Text] [Related]
39. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
40. Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study.
Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Apr; 35(5):68. PubMed ID: 29644504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
